Banco Bilbao Vizcaya Argentaria S.A. Raises Stake in Eli Lilly and Company $LLY

Banco Bilbao Vizcaya Argentaria S.A. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 18.8% in the second quarter, Holdings Channel reports. The institutional investor owned 41,313 shares of the company’s stock after buying an additional 6,544 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Eli Lilly and Company were worth $32,186,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Nixon Peabody Trust Co. boosted its position in shares of Eli Lilly and Company by 63.6% in the second quarter. Nixon Peabody Trust Co. now owns 19,510 shares of the company’s stock valued at $15,209,000 after acquiring an additional 7,588 shares during the period. Clearstead Trust LLC lifted its stake in Eli Lilly and Company by 1.2% in the 2nd quarter. Clearstead Trust LLC now owns 4,860 shares of the company’s stock worth $3,789,000 after purchasing an additional 57 shares in the last quarter. Wiser Advisor Group LLC boosted its holdings in Eli Lilly and Company by 1.8% in the 2nd quarter. Wiser Advisor Group LLC now owns 4,299 shares of the company’s stock valued at $3,351,000 after purchasing an additional 77 shares during the period. Allianz SE grew its position in shares of Eli Lilly and Company by 3.3% during the 2nd quarter. Allianz SE now owns 40,499 shares of the company’s stock valued at $31,570,000 after purchasing an additional 1,298 shares in the last quarter. Finally, Thompson Davis & CO. Inc. grew its position in shares of Eli Lilly and Company by 3.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 1,662 shares of the company’s stock valued at $1,296,000 after purchasing an additional 60 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,022.00 on Friday. The company has a 50-day simple moving average of $820.93 and a two-hundred day simple moving average of $779.85. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,032.95. The firm has a market cap of $966.19 billion, a price-to-earnings ratio of 66.80, a PEG ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Analyst Ratings Changes

LLY has been the subject of several research analyst reports. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $886.00 to $1,104.00 in a research note on Monday. Scotiabank started coverage on Eli Lilly and Company in a report on Thursday. They issued a “sector outperform” rating and a $1,165.00 price target on the stock. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $999.32.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.